Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 5.7% - Should You Buy?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report)'s share price shot up 5.7% on Monday . The company traded as high as $19.07 and last traded at $19.20. 628,792 shares traded hands during mid-day trading, a decline of 72% from the average session volume of 2,240,118 shares. The stock had previously closed at $18.17.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Barclays dropped their target price on Sarepta Therapeutics from $89.00 to $29.00 and set an "overweight" rating on the stock in a research report on Tuesday, June 17th. Deutsche Bank Aktiengesellschaft dropped their price target on Sarepta Therapeutics from $50.00 to $25.00 and set a "hold" rating on the stock in a report on Tuesday, June 17th. Evercore ISI downgraded shares of Sarepta Therapeutics from an "outperform" rating to an "inline" rating and set a $50.00 price target on the stock. in a research note on Thursday, May 8th. Piper Sandler cut shares of Sarepta Therapeutics from an "overweight" rating to a "neutral" rating and decreased their price target for the company from $70.00 to $36.00 in a report on Monday, June 16th. Finally, Oppenheimer reduced their target price on shares of Sarepta Therapeutics from $123.00 to $45.00 and set an "outperform" rating for the company in a research note on Friday, June 20th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and twelve have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $58.54.

Sarepta Therapeutics Stock Up 5.3%

The company has a market capitalization of $1.88 billion, a PE ratio of -7.09 and a beta of 0.45. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.02 and a quick ratio of 2.46. The company has a 50-day moving average of $30.98 and a two-hundred day moving average of $71.20.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing the consensus estimate of $2.20 by ($5.62). The company had revenue of $744.86 million for the quarter, compared to analysts' expectations of $685.75 million. Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. Sarepta Therapeutics's revenue for the quarter was up 80.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.73 earnings per share. Sell-side analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sarepta Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Steward Partners Investment Advisory LLC increased its holdings in shares of Sarepta Therapeutics by 164.4% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock worth $38,000 after purchasing an additional 194 shares during the last quarter. Byrne Asset Management LLC bought a new stake in shares of Sarepta Therapeutics in the first quarter worth about $30,000. Center for Financial Planning Inc. bought a new stake in shares of Sarepta Therapeutics in the first quarter worth about $31,000. Logan Capital Management Inc. bought a new stake in shares of Sarepta Therapeutics in the fourth quarter worth about $61,000. Finally, Ancora Advisors LLC increased its holdings in shares of Sarepta Therapeutics by 150.0% in the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 300 shares during the last quarter. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.